Transcatheter Interventions Online 2022 - On Demand
Published: 09 March 2022
Symposium: Optimising Outcomes for the TAVI Patient: Key Considerations for First Valve Choice and Implantation TechniquesUp Next
59m 47sPart 1 | Session 4 Session 1.3: Practical Perspectives in the Context of TAVI
1h 2m 44sPart 1 | Session 5 Session 1.4: Live Cases and Discussions
44m 31sPart 1 | Session 6 BREAKOUT: Current Data and Future Direction in LAAC
1h 1m 36sPart 2 | Session 1 Session 2.1: Strategies for Calcified Coronary Lesions Anno 2022
57m 43sPart 2 | Session 2 Session 2.2: Live Cases and Discussion
1h 1m 32sPart 2 | Session 4 Session 2.3: Practical Pearls Towards a More Advanced CTO Programme
56m 37sPart 2 | Session 5 Session 2.4: Live Cases and Discussion
45m 31sPart 2 | Session 7 BREAKOUT: Coronary Physiology in STEMI patients today: Why? When? How?
1h 32sPart 3 | Session 1 Session 3.1 & 3.2: Keynote & Controversies
59m 54sPart 3 | Session 2 Session 3.3: Live Cases and Discussion
1h 3m 33sPart 3 | Session 4 Session 3.4: Debates
1h 1m 7sPart 1 | Session 1 Session 1.1: Next Level Structural Heart Interventions Nicolas M Van Mieghem, Kendra J Grubb, Lars Søndergaard, Azeem Latib, David Hildick-Smith
1h 2m 19sPart 1 | Session 2 Session 1.2: Live Cases and Discussion Lars Søndergaard, Ole De Backer, Holger Thiele, Nicolas M Van Mieghem, Azeem Latib, Kendra J Grubb, David Hildick-Smith, Mohamed Abdel-Wahab
Following on from the success of 2021's inaugural edition, Transcatheter Interventions Online 2022 brings together a world-class faculty to provide expert insight and educational learning on the latest developments in interventional management.
Combining expert opinion and discussion, presentations, and live cases from centres on both sides of the Atlantic, TIO 2022 delivers best-in-class learning, supporting the latest in diagnosis, treatment strategies and patient management.
Note, the live version of this session was CME accredited; this on-demand version is not.
Key Learning Objectives
- Describe the practical implications of TAVI in the context of coronary artery disease, atrioventricular valve disease and transcatheter heart valve degeneration
- Select appropriate tools for calcified coronary artery disease, including mechanical circulatory support and invasive imaging techniques
- Understand coronary physiology, novel recanalization and goal-oriented planning for chronic total occlusion
- Evaluate the role of novel oral anticoagulants in transcatheter aortic valve implantation
- Discuss the need for gender-specific trials and renal denervation
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Day One: Structural Heart Disease
Day Two: Coronary Heart Disease: High Risk & Complex PCI
Day Three: Debates and Controversies
Didier Tchétché, (Clinique Pasteur, Toulouse, France) Graduated from the University of Paris V where Dr Tchétché obtained his post-graduate diploma of cardiovascular pathology in 2004. From 2004 to 2005, he completed a 12-month fellowship period in the Hemodynamic and Interventional Cardiology department of Clinique Pasteur in Toulouse and from 2005 to 2007 he was Head Assistant at the intensive care unit of Bichât Hospital in Paris.
In 2008, he joined the interventional cardiovascular group in Clinique Pasteur, Toulouse, and he is currently Head of the Structural programme with an experience of more than 5000 TAVI procedures. His main areas of interest are coronary interventions and valvular heart disease. He has been actively involved in many clinical trials involving new technologies and devices in the field of interventional cardiology.
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).
Prof Ran Kornowski, MD, FACC, FESC is the Director of the Cardiology Division at Rabin Medical Center (RMC) in Petach Tikva, Israel. He is a full Professor of Cardiovascular Medicine at the Faculty of Medicine, Tel Aviv University and until very recently he served as the President of the Israeli Heart Society.
Previously he also served as the Chairman of the Israeli Association of Interventional Cardiology 2009-13. Prof Kornowski established a cardiovascular research institute within his hospital conducting multiple clinical trials and translational research projects designated towards best innovative patient's care. He is a member of the leading cardiology societies worldwide.
Douglas G Fraser
Dr Douglas Fraser trained preclinical in Oxford and clinical in Cambridge, qualifying in 1991. House jobs in Addenbrooke’s, SHO and registrar training in the West Midlands including QE Birmingham, Walsgrave Coventry, North Staffordshire. One year fellowship in Amsterdam.
Recognised as expert in radial angioplasty. Active publication record in interventional cardiology